Lv5
1200 积分 2022-09-19 加入
Satralizumab treatment in patients with AQP4-IgG–seropositive neuromyelitis optica spectrum disorder after rituximab treatment: A case series
1天前
已完结
Beyond Glucocorticoids for IgG4-Related Disease
1天前
已完结
Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial
14天前
已完结
First‐in‐Human Study of BAT4406F, an ADCC‐Enhanced Fully Humanized Anti‐CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders
15天前
已完结
A breathtaking case of NMOSD: About pulmonary involvement in patients with AQP4-antibodies
15天前
已完结
Summary Gastro Digest: Can Inebilizumab change the management of IgG4-related Disease?
15天前
已完结
IgG4-related disease: lessons from the first 20 years
16天前
已完结
Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South Korea
16天前
已关闭
Hypogammaglobulinemia and Infection Events in Patients with Autoimmune Diseases Treated with Rituximab: 10 Years Real-Life Experience
17天前
已完结
Advances in maintenance therapies for neuromyelitis optica spectrum disorders: a new era of targeted drugs
23天前
已完结
皖公网安备34019202002308
